Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy

NCT03457142 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

15

Enrollment

OTHER

Sponsor class

Stopped funding ended

Conditions

Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions

BIOLOGICAL: Abatacept
DRUG: Dexamethasone
DRUG: Ixazomib Citrate
OTHER: Laboratory Biomarker Analysis

Sponsor

Roswell Park Cancer Institute

Collaborators

[object Object]